Advanced search
Publication Cover
Immunotherapy Volume 15, 2023 - Issue 18
Submit an article Journal homepage
39
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Immunotherapy for Head and Neck Cancer: Where do We Go from Here?

Eric C Ko1 Department of Radiation Oncology, University of Massachusetts Chan Medical School, UMass Memorial Medical Center, 55 Lake Avenue North, Worcester, MA01655, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2308-115XView further author information
ORCID Icon &
Glenn J Hanna2 Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USAView further author information
Pages 1497-1500 | Received 14 Aug 2023, Accepted 23 Oct 2023, Published online: 27 Nov 2023

References

  • Seiwert TY , BurtnessB , MehraRet al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol.17(7), 956–965 (2016).
  • Bauml J , SeiwertTY , PfisterDGet al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, Phase II study. J. Clin. Oncol.35(14), 1542–1549 (2017).
  • Ferris RL , BlumenscheinGJr , FayetteJet al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N. Engl. J. Med.375(19), 1856–1867 (2016).
  • Cohen EEW , SoulièresD , LeTourneau Cet al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet393(10167), 156–167 (2019).
  • Burtness B , HarringtonKJ , GreilRet al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet394(10212), 1915–1928 (2019).
  • Vermorken JB , MesiaR , RiveraFet al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med.359(11), 1116–1127 (2008).
  • Lee NY , FerrisRL , PsyrriAet al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol.22(4), 450–462 (2021).
  • Machiels JP , TaoY , BurtnessBet al. LBA5 Primary results of the phase III KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Ann. Oncol.33, S1399 (2022).
  • Bourhis J , TaoY , SunXet al. LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial. Ann. Oncol.32, S1310 (2021).
  • Harrington KJ , BurtnessB , GreilRet al. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J. Clin. Oncol.41(4), 790–802 (2023).
  • Pfister DG , HaddadRI , WordenFPet al. Biomarkers predictive of response to pembrolizumab in head and neck cancer. Cancer Med.12(6), 6603–6614 (2023).
  • Ang KK , HarrisJ , WheelerRet al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med.363(1), 24–35 (2010).
  • Shamseddine AA , BurmanB , LeeNY , ZamarinD , RiazN. Tumor immunity and immunotherapy for HPV-related cancers. Cancer Discov.11(8), 1896–1912 (2021).
  • Leemans CR , SnijdersPJF , BrakenhoffRH. The molecular landscape of head and neck cancer. Nat. Rev. Cancer.18(5), 269–282 (2018).
  • Darragh LB , GadwaJ , PhamTTet al. Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nat. Commun.13(1), 7015 (2022).
  • Fasano M , CorteCMD , LielloRDet al. Immunotherapy for head and neck cancer: present and future. Crit. Rev. Oncol. Hematol.174, 103679 (2022).
  • Harrington KJ , FerrisRL , GillisonMet al. Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the Phase 2 CheckMate 714 Randomized Clinical Trial. JAMA Oncol.9(6), 779–789 (2023).
  • Haddad RI , HarringtonK , TaharaMet al. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. J. Clin. Oncol.41(12), 2166–2180 (2023).
  • Larkin J , Chiarion-SileniV , GonzalezRet al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med.373(1), 23–34 (2015).
  • Wei SC , LevineJH , CogdillAPet al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell170(6), 1120–1133.e1117 (2017).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.